Singapore markets close in 2 hours 23 minutes
  • Straits Times Index

    3,257.38
    -2.65 (-0.08%)
     
  • Nikkei

    26,717.34
    +547.04 (+2.09%)
     
  • Hang Seng

    23,598.44
    -208.56 (-0.88%)
     
  • FTSE 100

    7,554.31
    +84.53 (+1.13%)
     
  • BTC-USD

    37,375.19
    +1,406.05 (+3.91%)
     
  • CMC Crypto 200

    848.65
    +29.14 (+3.56%)
     
  • S&P 500

    4,326.51
    -23.42 (-0.54%)
     
  • Dow

    34,160.78
    -7.31 (-0.02%)
     
  • Nasdaq

    13,352.78
    -189.34 (-1.40%)
     
  • Gold

    1,796.40
    +3.30 (+0.18%)
     
  • Crude Oil

    87.25
    +0.64 (+0.74%)
     
  • 10-Yr Bond

    1.8070
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,520.47
    +4.48 (+0.30%)
     
  • Jakarta Composite Index

    6,610.34
    -0.82 (-0.01%)
     
  • PSE Index

    7,251.97
    -21.55 (-0.30%)
     

Fuchs Endothelial Corneal Dystrophy (FECD) Epidemiology Forecasts, 2030 - ResearchAndMarkets.com

·4-min read

DUBLIN, November 30, 2021--(BUSINESS WIRE)--The "Fuchs Endothelial Corneal Dystrophy (FECD) - Epidemiology Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

This 'Fuchs Endothelial Corneal Dystrophy (FECD) - Epidemiology Forecast - 2030' report delivers an in-depth understanding of Fuchs Endothelial Corneal Dystrophy (FECD), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Fuchs Endothelial Corneal Dystrophy (FECD) Epidemiology

The Fuchs Endothelial Corneal Dystrophy (FECD) epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, trends, and assumptions.

Key Findings

The prevalent cases of Fuchs Endothelial Corneal Dystrophy (FECD) patients are increasing in 7MM during the study period, i.e., 2018-2030.

The disease epidemiology covered in the report provides historical as well as forecasted Fuchs Endothelial Corneal Dystrophy (FECD) symptoms epidemiology segmented as the Prevalent Cases of Fuchs Endothelial Corneal Dystrophy (FECD), Gender-specific cases of Fuchs Endothelial Corneal Dystrophy (FECD), and Age-specific Cases of Fuchs Endothelial Corneal Dystrophy (FECD).

The report includes the prevalent scenario of Fuchs Endothelial Corneal Dystrophy (FECD) symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Fuchs Endothelial Corneal Dystrophy (FECD) Epidemiology

The epidemiology segment also provides the Fuchs Endothelial Corneal Dystrophy (FECD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The prevalent cases of Fuchs Endothelial Corneal Dystrophy (FECD) in the 7MM were 17,386,186 in 2020 and are expected to grow at a CAGR of 0.66% during the study period.

  • As per the estimates, the United States has the largest prevalent population of Fuchs Endothelial Corneal Dystrophy (FECD).

  • Among the EU5 countries, Germany had the highest prevalent cases of Fuchs Endothelial Corneal Dystrophy (FECD), followed by Italy. On the other hand, Spain had the lowest incident cases with 1,258,137 cases in 2020.

Key Questions Answered

  • What will be the growth opportunities in the 7MM for the patient population about Fuchs Endothelial Corneal Dystrophy (FECD)?

  • What are the key findings of the Fuchs Endothelial Corneal Dystrophy (FECD) epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2018-2030)?

  • What would be the total number of Fuchs Endothelial Corneal Dystrophy (FECD) patients across the 7MM during the forecast period (2018-2030)?

  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2018-2030)?

  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2018-2030)?

  • What are the disease risk, burden, and unmet needs of Fuchs Endothelial Corneal Dystrophy (FECD)?

  • What are the currently available treatments for Fuchs Endothelial Corneal Dystrophy (FECD)?

Key Assessments

  • Patient Segmentation

  • Disease Risk and Burden

  • Risk of disease by the segmentation

  • Factors driving growth in a specific patient population

Key Topics Covered:

1 Key Insights

2 Report Introduction

3 Fuchs Endothelial Corneal Dystrophy (FECD) Market Overview at a Glance

3.1 Market Share (%) Distribution of Fuchs Endothelial Corneal Dystrophy (FECD) in 2018

3.2 Market Share (%) Distribution of Fuchs Endothelial Corneal Dystrophy (FECD) in 2030

4 Executive Summary of Fuchs Endothelial Corneal Dystrophy (FECD)

5 Disease Background and Overview

5.1 Introduction

5.2 Types of Corneal Dystrophies

5.3 Clinical Manifestations

5.4 Signs and Symptoms

5.5 Risk Factors

5.6 Genetics and Inheritance

5.7 Pathogenesis

5.8 Prognosis

5.9 Staging

5.1 Diagnosis

5.10.1 Diagnostic Criteria

5.10.2 Differential Diagnosis

5.11 Treatment and Management

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 7MM Total Prevalent Population of Fuchs Endothelial Corneal Dystrophy (FECD)

6.3 Epidemiology of Fuchs Endothelial Corneal Dystrophy (FECD)

6.4 The United States

6.4.1 Prevalent Cases of Fuchs Endothelial Corneal Dystrophy (FECD) in the United States

6.4.2 Gender-specific cases of Fuchs Endothelial Corneal Dystrophy (FECD) in the United States

6.4.3 Age-specific Cases of Fuchs Endothelial Corneal Dystrophy (FECD) in the United States

6.5 EU5

6.5.1 Germany

6.5.2 France

6.5.3 Italy

6.5.4 Spain

6.5.5 The United Kingdom

6.6 Japan

6.6.1 Prevalent Cases of Fuchs Endothelial Corneal Dystrophy (FECD) in Japan

6.6.2 Gender-specific cases of Fuchs Endothelial Corneal Dystrophy (FECD) in Japan

6.6.3 Age-specific Cases of Fuchs Endothelial Corneal Dystrophy (FECD) in Japan

7 Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/f81i7y

View source version on businesswire.com: https://www.businesswire.com/news/home/20211130005515/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting